pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Biotech & Pharma Sector, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Synthetic Biology
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Biotech & Pharma Sector, the most common co-covered peer. Source depth averages 2 original sources per story, versus 3.6 across the same-window beat baseline. At 5, the average consequence score sits below the same-window beat average of 6. Synthetic Biology appears in 1 tracked Biotech story from March 12, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 22 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Synthetic Biology. Shared-story counts are live from our verified record — not editorial picks.
New research suggests that species may possess a greater capacity for 'evolutionary rescue' than previously modeled, potentially averting climate-driven mass extinctions. This discovery has profound implications for the pharmaceutical industry's reliance on biodiversity and synthetic biology's efforts to engineer resilient organisms.